BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+32.57%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$9.65B
AUM Growth
+$9.65B
(+23%)
Cap. Flow
+$144M
Cap. Flow
% of AUM
1.49%
Top 10 Holdings %
Top 10 Hldgs %
77.89%
Holding
100
New
5
Increased
16
Reduced
3
Closed
6
Top Buys
| 1 |
Insmed
INSM
|
$61.3M |
| 2 |
CRISPR Therapeutics
CRSP
|
$34.9M |
| 3 |
Summit Therapeutics
SMMT
|
$26.3M |
| 4 |
Immunovant
IMVT
|
$21.7M |
| 5 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$21.2M |
Top Sells
| 1 |
HOOK
HOOKIPA Pharma
HOOK
|
$31.5M |
| 2 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$28M |
| 3 |
Aligos Therapeutics
ALGS
|
$17.3M |
| 4 |
Athira Pharma
ATHA
|
$8.36M |
| 5 |
TLIS
Talis Biomedical Corporation Common Stock
TLIS
|
$4.4M |
Sector Composition
| 1 | Healthcare | 98.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ONC
1
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $2.37B | 24.59% | 10,568,897 | – | – |
|
2
Incyte
INCY
$16.5B
| $2.03B | 21.06% | 30,739,020 +496 | +0% | +$32.8K |
|
3
Acadia Pharmaceuticals
ACAD
$4.38B
| $659M | 6.83% | 42,877,916 | – | – |
|
|
4
Summit Therapeutics
SMMT
$17.6B
| $535M | 5.54% | 24,424,865 +1,202,643 | +5% | +$26.3M |
|
5
Madrigal Pharmaceuticals
MDGL
$9.76B
| $419M | 4.34% | 1,974,590 | – | – |
|
6
Revolution Medicines
RVMD
$7.1B
| $343M | 3.56% | 7,569,090 | – | – |
|
7
Rhythm Pharmaceuticals
RYTM
$6.85B
| $335M | 3.47% | 6,398,366 +1 | +0% | +$52 |
|
|
8
Insmed
INSM
$28.8B
| $322M | 3.34% | 4,415,918 +839,880 | +23% | +$61.3M |
|
9
Kymera Therapeutics
KYMR
$2.95B
| $284M | 2.94% | 5,995,929 +1 | +0% | +$47 |
|
|
BCYC
10
Bicycle Therapeutics
BCYC
$511M
| $213M | 2.2% | 9,399,960 | – | – |
|
11
Edgewise Therapeutics
EWTX
$1.51B
| $156M | 1.62% | 5,840,059 | – | – |
|
12
Replimune Group
REPL
$422M
| $121M | 1.25% | 11,045,336 +1,000,000 | +10% | +$11M |
|
13
Alkermes
ALKS
$4.78B
| $117M | 1.21% | 4,181,751 | – | – |
|
14
Denali Therapeutics
DNLI
$2.23B
| $109M | 1.13% | 3,731,695 | – | – |
|
15
Ultragenyx Pharmaceutical
RARE
$2.89B
| $87.6M | 0.91% | 1,576,114 +109,567 | +7% | +$6.09M |
|
16
Nurix Therapeutics
NRIX
$714M
| $87.2M | 0.9% | 3,882,125 | – | – |
|
17
Entrada Therapeutics
TRDA
$208M
| $77.8M | 0.81% | 4,865,819 | – | – |
|
18
Immatics
IMTX
$619M
| $73.5M | 0.76% | 6,443,398 | – | – |
|
19
AbCellera Biologics
ABCL
$1.25B
| $71.6M | 0.74% | 27,525,640 | – | – |
|
20
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $70.4M | 0.73% | 2,818,323 | – | – |
|
|
IGMS
21
DELISTED
IGM Biosciences
IGMS
| $67.7M | 0.7% | 4,092,310 +1,994 | +0% | +$33K |
|
22
argenx
ARGX
$43.6B
| $60.7M | 0.63% | 111,904 | – | – |
|
23
Stoke Therapeutics
STOK
$1.08B
| $53.7M | 0.56% | 4,368,443 | – | – |
|
24
Immunocore
IMCR
$1.62B
| $47.2M | 0.49% | 1,515,318 | – | – |
|
25
Kodiak Sciences
KOD
$478M
| $45.2M | 0.47% | 17,310,490 | – | – |
|